- Scancell Holdings said that in 2017 it will concentrate on raising the necessary funds to enable the commencement of a Phase II SCIB1 trial in combination with a checkpoint inhibitor.

Scancell is a clinical stage pharmaceutical company developing two distinct flexible cancer immunotherapy platforms, each with broad applications.

ImmunoBody is a DNA vaccine which stimulates high avidity anti-tumour T-cells for use as a monotherapy or in combination with checkpoint inhibitors. Moditope targets modified antigens and stimulates powerful anti-tumour T-cell responses for use in advanced and hard-to-treat cancers.

At 9:56am: [LON:SCLP] Scancell Holdings PLC share price was +0.13p at 14.63p

Story provided by